PharmaCyte Biotech, Inc. SEC filings PMCB
PharmaCyte Biotech, Inc. has 472 filings in SEC EDGAR's recent list, going back to Aug 20, 2001. Its latest annual report, Form 10-K, was filed on Jul 29, 2026 for the period ended Apr 30, 2026. The latest quarterly report (Form 10-Q) was filed on Sep 14, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (auditor change). The company's fiscal year ends on April 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4/A | Filing | Jul 17, 2026 | Mar 31, 2026 |
| 4/A | Filing | Jul 17, 2026 | Mar 31, 2026 |
| 4/A | Filing | Jul 17, 2026 | Mar 31, 2026 |
| 4/A | Filing | Jul 17, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Mar 18, 2026 | Mar 17, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 18, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Jan 7, 2026 | Jan 5, 2026 |
| 4 | Insider transaction | Jan 7, 2026 | Jan 5, 2026 |
| 4 | Insider transaction | Dec 12, 2025 | Apr 25, 2025 |
| 4 | Insider transaction | Dec 12, 2025 | Apr 25, 2025 |
| 4 | Insider transaction | Dec 12, 2025 | Dec 12, 2025 |
| 4 | Insider transaction | Dec 12, 2025 | Apr 25, 2025 |
| 4 | Insider transaction | Dec 12, 2025 | Apr 25, 2025 |
| 4 | Insider transaction | Nov 18, 2025 | Sep 4, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 18, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 15, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 13, 2024 | — |
| 4 | Insider transaction | Jul 17, 2024 | Apr 30, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Apr 30, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Apr 30, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Apr 30, 2024 |
| 3 | Initial insider ownership | May 30, 2024 | May 23, 2024 |
| SC 13D | Ownership over 5% (active) | May 30, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 6, 2024 | — |
| 3 | Initial insider ownership | Nov 28, 2023 | Nov 21, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| 4 | Insider transaction | Nov 22, 2023 | Nov 20, 2023 |
| SC 13D | Ownership over 5% (active) | Nov 22, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 16, 2023 | — |
| SC 13G | Ownership over 5% (passive) | May 19, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 12, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 8, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 10, 2023 | — |
| 3 | Initial insider ownership | Dec 30, 2022 | Dec 28, 2022 |
| 4 | Insider transaction | Dec 30, 2022 | Dec 28, 2022 |
| 4 | Insider transaction | Dec 30, 2022 | Dec 28, 2022 |
| 3 | Initial insider ownership | Nov 16, 2022 | Nov 14, 2022 |
| SC 13G | Ownership over 5% (passive) | Oct 20, 2022 | — |
| 3 | Initial insider ownership | Aug 24, 2022 | Aug 15, 2022 |
| 3 | Initial insider ownership | Aug 23, 2022 | Aug 15, 2022 |
| 3 | Initial insider ownership | Aug 23, 2022 | Aug 15, 2022 |
| 3 | Initial insider ownership | Aug 23, 2022 | Aug 15, 2022 |
| 3 | Initial insider ownership | Aug 23, 2022 | Aug 15, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Aug 15, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jul 11, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jun 23, 2022 | — |
| 3 | Initial insider ownership | Apr 11, 2022 | Mar 31, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 4, 2022 | — |
| SC 13D | Ownership over 5% (active) | Nov 4, 2021 | — |
| 3 | Initial insider ownership | Sep 3, 2021 | Aug 10, 2021 |
| 3 | Initial insider ownership | Aug 31, 2021 | Aug 10, 2021 |
| 3 | Initial insider ownership | Aug 31, 2021 | Aug 10, 2021 |
| 3 | Initial insider ownership | Aug 31, 2021 | Aug 10, 2021 |
| SC 13G | Ownership over 5% (passive) | Aug 30, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Aug 30, 2021 | — |
| 3 | Initial insider ownership | Aug 20, 2021 | Aug 10, 2021 |
| 3 | Initial insider ownership | Aug 20, 2021 | Aug 10, 2021 |
| 3 | Initial insider ownership | Aug 20, 2021 | Aug 10, 2021 |
| SC 13D/A | Amended ownership over 5% (active) | Jul 29, 2020 | — |
| SC 13D | Ownership over 5% (active) | May 6, 2020 | — |
| 3 | Initial insider ownership | Mar 30, 2009 | Mar 17, 2009 |
| 3 | Initial insider ownership | Mar 30, 2009 | Mar 17, 2009 |
Showing 76 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.